San Francisco, CA -- (SBWIRE) -- 01/20/2015 -- Arrowhead Business and Investment Decisions, LLC ("Arrowhead") initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company") (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014.
The report is available under the following link.
Please click here for more information on Accurexa Inc.
Research Report Highlights
Arrowhead is initiating coverage on Accurexa Inc. with a fair value bracket of $3.83 (Low-Bracket estimate) and $9.27 (High-Bracket estimate). Highlights of this report include the following:
-The Company has entered into an exclusive licensing agreement with the University of California, San Francisco (UCSF), for a medical stereotactic device for the delivery of therapeutics to the human brain, known as BranchPoint device. The Company is planning to file 510(K) FDA application in Q12015
-The growing global Stem Cell market and the increasing number of Parkinson's and Brain Cancer patients is expected to drive demand for the BranchPoint device
-The Company has also signed a LOI with a stem cell manufacturer to develop stem cell treatment for Parkinson's and is in the process of initiating a Brain Cancer Program
-Around 20 companies are developing 42 neural stem cell trial programs representing an addressable potential market size of US$5MM. Applying an 66% POS and a 33% market share, the market potential of Accurexa is round US$1MM
-Revenue from the Company's Brain Cancer indication is expected to start by 2020 and is likely to peak by 2025 while Revenue from the Company's Parkinson's indication could start by 2025 and is likely to peak by 2030
About Accurexa, Inc.
The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. The BranchPoint device delivers therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can "tailor" therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies. The BranchPoint device also gives physicians more precise control of the volume of therapeutics delivered and ensures that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. This modern and "easy to use" technology allows "real-time" monitoring of therapeutic delivery under interventional MRI guidance (iMRI), which can improve the accuracy of therapeutic delivery, reduce the risk of complications, and increase patient safety.
The BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform, which the Company exclusively licensed from UCSF. It can enable new approaches to neurological therapy and be modified for the delivery of a wide range of novel therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors or gene therapy.
Additional information about the Company may be found on its website, http://www.accurexa.com/
Safe Harbor Statement
Statements contained and linked to this news release are not historical facts, they are forward-looking statements. Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from estimated results. Forward-looking statements are based on the beliefs, estimates and opinions of Arrowhead analysts on the date the statements are made. Arrowhead undertakes no obligation to update these forward-looking statements if beliefs, estimates or opinions, or other factors, should change. The information contained and linked to this news release is purely factual and does not constitute a recommendation to buy or sell securities. Arrowhead received fees in 2014 and will receive fees in 2015 from Accurexa for the research costs and other services including publishing this report and investor relations services. Arrowhead is not responsible for any loss, financial or other, directly or indirectly linked to any price movement or absence of price movement of the securities described. Please refer to the disclaimer page in the report for other important disclosures and analyst certifications.
For further information:
Arrowhead Business and Investment Decisions, LLC
Thomas Renaud, 212-619-6889
Daniel Renaud, 212-619-6889
Source: UPTICK Newswire